Overview A Study of ABTL0812 in Pancreatic Cancer Status: Not yet recruiting Trial end date: 2023-03-30 Target enrollment: Participant gender: Summary A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy. Phase: Phase 1/Phase 2 Details Lead Sponsor: Ability Pharmaceuticals SLCollaborator: The Cleveland ClinicTreatments: Albumin-Bound PaclitaxelGemcitabinePaclitaxel